Prior Research

Abzug MJ, Levin MJ, Rotbart HA. Profile of enterovirus disease in the first two weeks of life. Pediatr Infect Dis J. 1993;12:820-4.

Abzug MJ, Michaels MG, Wald E, Jacobs RF, Romero JR, Sanchez PJ, Wilson G, Krogstad P, Storch GA, Lawrence R, Shelton M, Palmer A, Robinson J, Dennehy P, Sood SK, Cloud G, Jester P, Acosta EP, Whitley R, Kimberlin D. A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis. J Pediatric Infect Dis Soc. 2016;5:53-62. doi: 10.1093/jpids/piv015. Epub 2015 Apr 16.

Abzug MJ. Prognosis for neonates with enterovirus hepatitis and coagulopathy. Pediatr Infect Dis J. 2001;20:758-63.

Aizawa Y, Izumita R, Saitoh A. Human parechovirus type 3 infection: An emerging infection in neonates and young infants. J Infect Chemother. 2017;23:419-426. doi: 10.1016/j.jiac.2017.04.009. Epub 2017 May 13.

Bauer L, Lyoo H, van der Schaar HM, Strating JR, van Kuppeveld FJ. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections. Curr Opin Virol. 2017;24:1-8.:10.1016/j.coviro.2017.03.009. Epub 2017 Apr 12.

Braccio S, Kapetanstrataki M, Sharland M, Ladhani SN. Intensive Care Admissions for Children With Enterovirus and Human Parechovirus Infections in the United Kingdom and The Republic of Ireland, 2010-2014. Pediatr Infect Dis J. 2017;36:339-342. doi: 10.1097/INF.0000000000001430.

Cabrerizo M, Trallero G, Pena MJ, Cilla A, Megias G, Munoz-Almagro C, Del Amo E, Roda D, Mensalvas AI, Moreno-Docon A, Garcia-Costa J, Rabella N, Omenaca M, Romero MP, Sanbonmatsu-Gamez S, Perez-Ruiz M, Santos-Munoz MJ, Calvo C. Comparison of epidemiology and clinical characteristics of infections by human parechovirus vs. those by enterovirus during the first month of life. Eur J Pediatr. 2015;174:1511-6. doi: 10.1007/s00431-015-2566-9. Epub 2015 May 16.

Cilla A, Megias G, Suarez J, Ojeda E, Cabrerizo M, Arnaez J. Human parechovius and enterovirus in neonates: Distinct infections with overlapping features. Early Hum Dev. 2015;91:475-8. doi: 10.1016/j.earlhumdev.2015.05.005. Epub 2015 Jun 10.

Dagan R, Hall CB, Powell KR, Menegus MA. Epidemiology and laboratory diagnosis of infection with viral and bacterial pathogens in infants hospitalized for suspected sepsis. J Pediatr. 1989;115:351-6.

de Jong EP, Holscher HC, Steggerda SJ, Van Klink JMM, van Elzakker EPM, Lopriore E, Walther FJ, Brus F. Cerebral imaging and neurodevelopmental outcome after entero-and human parechovirus sepsis in young infants. Eur J Pediatr. 2017;176:1595-1602. doi: 10.1007/s00431-017-2981-1. Epub 2017 Sep 10.

Freund MW, Kleinveld G, Krediet TG, van Loon AM, Verboon-Maciolek MA. Prognosis for neonates with enterovirus myocarditis. Arch Dis Child Fetal Neonatal Ed. 2010;95:F206-12. doi: 10.1136/adc.2009.165183.

Greninger AL, Messacar K, Dunnebacke T, Naccache SN, Federman S, Bouquet J, Mirsky D, Nomura Y, Yagi S, Glaser C, Vollmer M, Press CA, Kleinschmidt-DeMasters BK, Dominguez SR, Chiu CY. Clinical metagenomic identification of Balamuthia mandrillaris encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing. Genome Med. 2015;7:113.:10.1186/s13073-015-0235-2.

Greninger AL, Messacar K, Dunnebacke T, Naccache SN, Federman S, Bouquet J, Mirsky D, Nomura Y, Yagi S, Glaser C, Vollmer M, Press CA, Kleinschmidt-DeMasters BK, Dominguez SR, Chiu CY. Erratum to: Clinical metagenomic identification of Balamuthia mandrillaris encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing. Genome Med. 2016;8:1. doi: 10.1186/s13073-015-0257-9.

Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, Federman S, Stryke D, Anderson C, Yagi S, Messenger S, Wadford D, Xia D, Watt JP, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14): a retrospective cohort study. Lancet Infect Dis. 2015;15:671-82. doi: 10.1016/S1473-3099(15)70093-9. Epub 2015 Mar 31.

Inwald D, Franklin O, Cubitt D, Peters M, Goldman A, Burch M. Enterovirus myocarditis as a cause of neonatal collapse. Arch Dis Child Fetal Neonatal Ed. 2004;89:F461-2. doi: 10.1136/adc.2003.034439.

Isacsohn M, Eidelman AI, Kaplan M, Goren A, Rudensky B, Handsher R, Barak Y. Neonatal coxsackievirus group B infections: experience of a single department of neonatology. Isr J Med Sci. 1994;30:371-4.

Jenista JA, Powell KR, Menegus MA. Epidemiology of neonatal enterovirus infection. J Pediatr. 1984;104:685-90.

Khatami A, McMullan BJ, Webber M, Stewart P, Francis S, Timmers KJ, Rodas E, Druce J, Mehta B, Sloggett NA, Cumming G, Papadakis G, Kesson AM. Sepsis-like disease in infants due to human parechovirus type 3 during an outbreak in Australia. Clin Infect Dis. 2015;60:228-36. doi: 10.1093/cid/ciu784. Epub 2014 Oct 9.

Khetsuriani N, Lamonte A, Oberste MS, Pallansch M. Neonatal enterovirus infections reported to the national enterovirus surveillance system in the United States, 1983-2003. Pediatr Infect Dis J. 2006;25:889-93. doi: 10.1097/01.inf.0000237798.07462.32.

Kimura H, Minakami H, Harigaya A, Takeuchi H, Tachibana A, Otsuki K. Treatment of neonatal infection caused by coxsackievirus B3. J Perinatol. 1999;19:388-90.

Krajden S, Middleton PJ. Enterovirus infections in the neonate. Clinical Pediatrics. 1983;22:87-92.

Kurz H, Prammer R, Bock W, Ollerieth R, Bernert G, Zwiauer K, Aberle JH, Aberle SW, Fazekas T, Holter W. Intracranial hemorrhage and other symptoms in infants associated with human parechovirus in Vienna, Austria. Eur J Pediatr. 2015;174:1639-47. doi: 10.1007/s00431-015-2583-8. Epub 2015 Jun 25.

Lake AM, Lauer BA, Clark JC, Wesenberg RL, McIntosh K. Enterovirus infections in neonates. J Pediatr. 1976;89:787-91.

Lin TY, Kao HT, Hsieh SH, Huang YC, Chiu CH, Chou YH, Yang PH, Lin RI, Tsao KC, Hsu KH, Chang LY. Neonatal enterovirus infections: emphasis on risk factors of severe and fatal infections. Pediatr Infect Dis J. 2003;22:889-94. doi: 10.1097/01.inf.0000091294.63706.f3.

Modlin JF. Perinatal echovirus infection: insights from a literature review of 61 cases of serious infection and 16 outbreaks in nurseries. Rev Infect Dis. 1986;8:918-26.

Sano K, Hamada H, Hirose S, Sugiura K, Harada S, Koizumi M, Hara M, Nishijima H, Taira M, Ogura A, Ogawa T, Takanashi JI. Prevalence and characteristics of human parechovirus and enterovirus infection in febrile infants. Pediatr Int. 2018;60:142-147. doi: 10.1111/ped.13467.

Saporta-Keating SR, Simoes EAF, Yu G, Federman S, Mirsky D, Dominguez SR, Chiu CY, Messacar K. A Child With Intermittent Headaches and Eosinophilic Meningitis. J Pediatric Infect Dis Soc. 2018;9.

Shakeel S, Westerhuis BM, Domanska A, Koning RI, Matadeen R, Koster AJ, Bakker AQ, Beaumont T, Wolthers KC, Butcher SJ. Multiple capsid-stabilizing interactions revealed in a high-resolution structure of an emerging picornavirus causing neonatal sepsis. Nat Commun. 2016;7:11387.:10.1038/ncomms11387.

van der Linden L, Wolthers KC, van Kuppeveld FJ. Replication and Inhibitors of Enteroviruses and Parechoviruses. Viruses. 2015;7:4529-62. doi: 10.3390/v7082832.

Verboon-Maciolek MA, Swanink CM, Krediet TG, van Loon AM, Bruning HJ, Kaan JA, Gerards LJ, Galama JM, Fleer A. Severe neonatal echovirus 20 infection characterized by hepatic failure. Pediatr Infect Dis J. 1997;16:524-7.

Wang J, Atchison RW, Walpusk J, Jaffe R. Echovirus hepatic failure in infancy: report of four cases with speculation on the pathogenesis. Pediatr Dev Pathol. 2001;4:454-60.

Cannon MJ, Griffiths PD, Aston V, Rawlinson WD. Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit? Rev Med Virol. 2014;24:291-307. doi: 10.1002/rmv.1790. Epub 2014 Apr 24.

Centers for Disease Control and Prevention. U.S. public health impact of congenital cytomegalovirus infection. MMWR - CcenterwDC Surveillance Summaries. 1992;41:35-39.

Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhauser M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, Kolling K, Stobernack HP, Lischka P, Zimmermann H, Rubsamen-Schaeff H, Champlin RE, Ehninger G. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370:1781-9. doi: 10.1056/NEJMoa1309533.

Chou S. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. Antiviral Res. 2017;148:1-4.:10.1016/j.antiviral.2017.10.019. Epub 2017 Oct 28.

Cocohoba JM, McNicholl IR. Valganciclovir: an advance in cytomegalovirus therapeutics. Annals of Pharmacotherapy. 2002;36:1075-9.

Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. American Journal of Medicine. 1992;92:3S-7S.

Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJ, Jaffe HS. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrobial Agents & Chemotherapy. 1995;39:1247-52.

Dahle AJ, Fowler KB, Wright JD, Boppana SB, Britt WJ, Pass RF. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. Journal of the American Academy of Audiology. 2000;11:283-90.

Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17:355-363.

Elek SD, Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet. 1974;1:1-5.

Fowler KB, Boppana SB. Congenital cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol. 2006;35:226-31.

Fowler KB, Dahle AJ, Boppana SB, Pass RF. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed? Journal of Pediatrics. 1999;135:60-4.

Fowler KB, McCollister FP, Dahle AJ, Boppana S, Britt WJ, Pass RF. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. Journal of Pediatrics. 1997;130:624-30.

Fowler KB, Ross SA, Shimamura M, Ahmed A, Palmer AL, Michaels MG, Bernstein DI, Sanchez PJ, Feja KN, Stewart A, Boppana S. Racial and Ethnic Differences in the Prevalence of Congenital Cytomegalovirus Infection. J Pediatr. 2018;200:196-201.e1.:10.1016/j.jpeds.2018.04.043. Epub 2018 May 18.

Ganciclovir Package Insert. http://www.gene.com/gene/products/information/cytovene/pdf/pi.pdf. Accessed March 8.

Gilbert SR, Gilbert AC, Henderson RC. Skeletal maturation in children with quadriplegic cerebral palsy. J Pediatr Orthop. 2004;24:292-7.

Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85:10884-93. doi: 10.1128/JVI.05265-11. Epub 2011 Jul 13.

Gollapudi K, Feeley BT, Otsuka NY. Advanced skeletal maturity in ambulatory cerebral palsy patients. J Pediatr Orthop. 2007;27:295-8.

Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin Virol. 2008;41:57-62.

Henderson RC, Gilbert SR, Clement ME, Abbas A, Worley G, Stevenson RD. Altered skeletal maturation in moderate to severe cerebral palsy. Dev Med Child Neurol. 2005;47:229-36.

Ho HT, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJ. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Molecular Pharmacology. 1992;41:197-202.

Ihkkan DY, Yalcin E. Changes in skeletal maturation and mineralization in children with cerebral palsy and evaluation of related factors. J Child Neurol. 2001;16:425-30.

James SH, Hartline CB, Daily SL, Frederick SL, Kimberlin DW, Whitley RJ, Prichard MN. Genotypic resistance testing of cytomegalovirus DNA in congenitally infected infants after 6 weeks of treatment with ganciclovir/valganciclovir, 47th Annual Meeting of The Infectious Diseases Society of America (IDSA), Philadelphia, Pennsylvania, October 31, 2009:Abstract #711

James SH, Hartline CB, Kimberlin DW, Whitley RJ, Prichard MN. Genotypic Resistance Testing in Infants with Congenital Cytomegalovirus Disease Receiving Long-Term Oral Valganciclovir Therapy, IDWeek 2015 (annual meeting of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, the HIV Medicine Association and the Society for Healthcare Epidemiology of America), San Diego, CA, October 8, 2015:Abstract #476

James SH, Kimberlin DW, Hartline CB, Driebe EM, Schupp JM, Engelthaler DM, Keim PS, Whitley RJ, Prichard MN. Longitudinal Assessment of Genotypic Resistance by Deep Sequencing of Cytomegalovirus DNA in Congenitally Infected Infants Treated with Valganciclovir, 49th Annual Meeting of The Infectious Diseases Society of America (IDSA), Boston, Massachussetts, October 20-23, 2011:Abstract 1215

Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17:253-76.

Kimberlin DW, Acosta EP, Sanchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud GA, Lakeman FD, Whitley RJ. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008;197:836-45.

Kimberlin DW, Jacobs RF, Weller S, van der Walt JS, Heitman CK, Man CY, Bradley JS. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age. Clin Infect Dis. 2010;50:221-8.

Kimberlin DW, Jester PM, Sanchez PJ, Ahmed A, Arav-Boger R, Michaels MG, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth MS, Abzug MJ, Caserta MT, Fowler S, Lujan-Zilbermann J, Storch GA, DeBiasi RL, Han JY, Palmer A, Weiner LB, Bocchini JA, Dennehy PH, Finn A, Griffiths PD, Luck S, Gutierrez K, Halasa N, Homans J, Shane AL, Sharland M, Simonsen K, Vanchiere JA, Woods CR, Sabo DL, Aban I, Kuo H, James SH, Prichard MN, Griffin J, Giles D, Acosta EP, Whitley RJ. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015;372:933-43. doi: 10.1056/NEJMoa1404599.

Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Pass RF, Kiell JM, Soong SJ, Whitley RJ, for the National Institute of Allergy Infectious Diseases Collaborative Antiviral Study Group. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. Journal of Pediatrics. 2003;143:16-25.

Kong CK, Tse PW, Lee WY. Bone age and linear skeletal growth of children with cerebral palsy. Dev Med Child Neurol. 1999;41:758-65.

Kropeit D, von Richter O, Stobernack HP, Rubsamen-Schaeff H, Zimmermann H. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. Clin Pharmacol Drug Dev. 2018;7:9-21. doi: 10.1002/cpdd.388. Epub 2017 Oct 2.

Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. Journal of Infectious Diseases. 1995;171:788-96.

Letermovir Package Insert. https://www.merck.com/product/usa/pi_circulars/p/prevymis/prevymis_pi.pdf. October 4, 2018.

Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, Ruebsamen-Schaeff H, Zimmermann H. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.

Antimicrob Agents Chemother. 2010;54:1290-7. doi: 10.1128/AAC.01596-09. Epub 2010 Jan 4.

Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26:86-102.

Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017;377:2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6.

Morton CC, Nance WE. Newborn hearing screening--a silent revolution. N Engl J Med. 2006;354:2151-64.

Rawlinson WD, Boppana SB, Fowler KB, Kimberlin DW, Lazzarotto T, Alain S, Daly K, Doutre S, Gibson L, Giles ML, Greenlee J, Hamilton ST, Harrison GJ, Hui L, Jones CA, Palasanthiran P, Schleiss MR, Shand AW, van Zuylen WJ. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017;10:30143-3.

Reefschlaeger J, Bender W, Hallenberger S, Weber O, Eckenberg P, Goldmann S, Haerter M, Buerger I, Trappe J, Herrington JA, Haebich D, Ruebsamen-Waigmann H. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. Journal of Antimicrobial Chemotherapy. 2001;48:757-67.

Trang JM, Kidd L, Gruber W, Storch G, Demmler G, Jacobs R, Dankner W, Starr S, Pass R, Stagno S, Alford C, Soong SJ, Whitley RJ, Sommadossi JP, for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Clinical Pharmacology & Therapeutics. 1993;53:15-21.

United States Department of Labor. Bureau of Labor Statistics CPI Inflation Calculator.  http://www.bls.gov/data/inflation_calculator.htm. April 29, 2015

Valganciclovir Package Insert. http://www.gene.com/download/pdf/valcyte_prescribing.pdf. May 1, 2015

Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994;48:199-226.

Weber O, Bender W, Eckenberg P, Goldmann S, Haerter M, Hallenberger S, Henninger K, Reefschlager J, Trappe J, Witt-Laido A, Ruebsamen-Waigmann H. Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Research. 2001;49:179-89.

Whitley RJ, Cloud G, Gruber W, Storch GA, Demmler GJ, Jacobs RF, Dankner W, Spector SA, Starr S, Pass RF, Stagno S, Britt WJ, Alford C, Jr., Soong S, Zhou XJ, Sherrill L, FitzGerald JM, Sommadossi JP, for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. Journal of Infectious Diseases. 1997;175:1080-6.

Williamson WD, Desmond MM, LaFevers N, Taber LH, Catlin FI, Weaver TG. Symptomatic congenital cytomegalovirus. Disorders of language, learning, and hearing. American Journal of Diseases of Children. 1982;136:902-5.

Worley G, Houlihan CM, Herman-Giddens ME, O'Donnell ME, Conaway M, Stallings VA, Chumlea WC, Henderson RC, Fung EB, Rosenbaum PL, Samson-Fang L, Liptak GS, Calvert RE, Stevenson RD. Secondary sexual characteristics in children with cerebral palsy and moderate to severe motor impairment: a cross-sectional survey. Pediatrics. 2002;110:897-902.

Yow MD, Demmler GJ. Congenital cytomegalovirus disease--20 years is long enough. New England Journal of Medicine. 1992;326:702-3.

Zhou XJ, Gruber W, Demmler G, Jacobs R, Reuman P, Adler S, Shelton M, Pass R, Britt B, Trang JM, Whitley RJ, Sommadossi JP, for the NIAID Collaborative Antiviral Study Group. Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Antimicrobial Agents & Chemotherapy. 1996;40:2202-5.

ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists. Management of herpes in pregnancy. Obstet Gynecol. 2007;109:1489-1498.

Acyclovir [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2005.

American Academy of Pediatrics. Herpes simplex. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2015:432-445.

American Academy of Pediatrics. Herpes simplex. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Elk Grove Village, IL: American Academy of Pediatrics, 2018:437-449.

American Academy of Pediatrics. Herpes simplex. In: Peter J, ed. 1991 Red Book: Report of the Committee on Infectious Diseases. 22nd ed. Elk Grove Village, IL: American Academy of Pediatrics, 1991:259-269.

American Academy of Pediatrics. Herpes simplex. In: Peter J, ed. 1994 Red Book: Report of the Committee on Infectious Diseases. 23th ed. Elk Grove Village, IL: American Academy of Pediatrics, 1994:242-252.

American Academy of Pediatrics. Herpes simplex. In: Peter J, ed. 1997 Red Book: Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics, 1997:266-276.

American Academy of Pediatrics. Herpes simplex. In: Pickering LK, Baker CJ, Long SS, Kimberlin DW, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2012:398-408.

American Academy of Pediatrics. Herpes simplex. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000:309-318.

American Academy of Pediatrics. Herpes simplex. In: Pickering LK, ed. 2003 Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2003:344-353.

American Academy of Pediatrics. Herpes simplex. In: Pickering LK, ed. 2006 Red Book: Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2006:361-371.

Bernstein DI, Bellamy AR, Hook EW, 3rd, Levin MJ, Wald A, Ewell MG, Wolff PA, Deal CD, Heineman TC, Dubin G, Belshe RB. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis. 2013;56:344-51.

Braig S, Luton D, Sibony O, Edlinger C, Boissinot C, Blot P, Oury JF. Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding. Eur J Obstet Gynecol Reprod Biol. 2001;96:55-8.

Brocklehurst P, Kinghorn G, Carney O, Helsen K, Ross E, Ellis E, Shen R, Cowan F, Mindel A. A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. British Journal of Obstetrics & Gynaecology. 1998;105:275-80.

Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, Berry S, Vontver LA, Corey L. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1991;324:1247-52.

Brown ZA, Vontver LA, Benedetti J, Critchlow CW, Sells CJ, Berry S, Corey L. Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med. 1987;317:1246-51.

Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA. 2003;289:203-9.

Elion GB. Mechanism of action and selectivity of acyclovir. American Journal of Medicine. 1982;73:7-13.

Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. Sexually Transmitted Diseases. 2003;30:174-7.

Jacobson MA. Valaciclovir (BW256U87): the L-valyl ester of acyclovir. Journal of Medical Virology. 1993;Suppl:150-3.

Kimberlin DW, Baley J. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics. 2013;131:e635-46.

Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA, Burchett SK, Jacobs RF, Starr SE, Whitley RJ, The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. J Infect Dis. 1996;174:1162-7.

Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, Gruber WC, Rathore M, Bradley JS, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, de Sierra TM, Weller S, Soong SJ, Kiell J, Lakeman FD, Whitley RJ, The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics. 2001;108:230-8.

Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Frenkel LM, Gruber WC, Rathore M, Bradley JS, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, de Sierra TM, Soong SJ, Kiell J, Lakeman FD, Whitley RJ, The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics. 2001;108:223-9.

Kimberlin DW, Rouse DJ. Genital herpes. N Engl J Med. 2004;350:1970-7.

Kimberlin DW, Whitley RJ, Wan W, Powell DA, Storch G, Ahmed A, Palmer A, Sánchez PJ, Jacobs RJ, Bradley JS, Robinson JL, Shelton M, Dennehy PH, Leach C, Rathore M, Abughali N, Wright P, Frenkel LM, Brady RC, Van Dyke R, Weiner LB, Guzman-Cottrill J, McCarthy CA, Griffin J, Jester P, Parker M, Lakeman FD, Kuo H, Lee CH, Cloud GA, for the NIAID Collaborative Antiviral Study Group. Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med. 2011;365:1284-1292.

Kimberlin DW. Neonatal herpes simplex infection. Clin Microbiol Rev. 2004;17:1-13.

Kimberlin DW. The Scarlet H. J Infect Dis. 2014;209:315-317.

McQuillan G, Kruszon-Moran D, Flagg EW, Paulose-Ram R. Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14-49: United States, 2015-2016. NCHS Data Brief. 2018:1-8.

Morse GD, Shelton MJ, O'Donnell AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clinical Pharmacokinetics. 1993;24:101-23.

Nahmias AJ, Josey WE, Naib ZM, Freeman MG, Fernandez RJ, Wheeler JH. Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol. 1971;110:825-37.

Pinninti SG, Angara R, Feja KN, Kimberlin DW, Leach CT, Conrad DA, McCarthy CA, Tolan RW, Jr. Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series. J Pediatr. 2012;161:134-8 e1-3.

Reardon JE, Spector T. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. Journal of Biological Chemistry. 1989;264:7405-11.

Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD, Jr. Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect Dis Obstet Gynecol. 2002;10:71-7.

Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD, Jr. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet Gynecol. 1996;87:69-73.

Sheffield JS, Hill JB, Hollier LM, Laibl VR, Roberts SW, Sanchez PJ, Wendel GDJ. Valacyclovir Prophylaxis to Prevent Recurrent Herpes at Delivery: A Randomized Clinical Trial. Obstet Gynecol. 2006;108:141-147.

Sheffield JS, Wendel GDJ, Laibl VR, Roberts SW, Sanchez PJ, Hollier LM, Hill JB. Valacyclovir Prophylaxis to Prevent Recurrent Herpes at Delivery: A Randomized Clinical Trial. Obstet Gynecol. 2006;108:1550-1552.

Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrobial Agents & Chemotherapy. 1995;39:2759-64.

Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, Aoki FY, Lacey CJ. Prospects for control of herpes simplex virus disease through immunization. Clinical Infectious Diseases. 2000;30:549-66.

Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G, The GlaxoSmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347:1652-61.

Wagstaff AJ, Faulds D, Goa KL. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994;47:153-205.

Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, Smiley ML. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clinical Pharmacology & Therapeutics. 1993;54:595-605.

Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D, Plotkin S, Starr S, Alford C, Connor J, The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Engl J Med. 1991;324:444-9.

Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D, Plotkin S, Starr S, Alford C, Connor J, The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Engl J Med. 1991;324:444-9.

Whitley R, Arvin A, Prober C, Corey L, Burchett S, Plotkin S, Starr S, Jacobs R, Powell D, Nahmias A, The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. N Engl J Med. 1991;324:450-4.

Whitley R, Hilty M, Haynes R, Bryson Y, Connor JD, Soong SJ, Alford CA. Vidarabine therapy of varicella in immunosuppressed patients. Journal of Pediatrics. 1982;101:125-31.

Whitley RJ, Corey L, Arvin A, Lakeman FD, Sumaya CV, Wright PF, Dunkle LM, Steele RW, Soong SJ, Nahmias AJ. Changing presentation of herpes simplex virus infection in neonates. J Infect Dis. 1988;158:109-16.

Whitley RJ, Nahmias AJ, Soong SJ, Galasso GG, Fleming CL, Alford CA. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics. 1980;66:495-501.

Whitley RJ, Nahmias AJ, Visintine AM, Fleming CL, Alford CA. The natural history of herpes simplex virus infection of mother and newborn. Pediatrics. 1980;66:489-94.

Whitley RJ, Yeager A, Kartus P, Bryson Y, Connor JD, Alford CA, Nahmias A, Soong SJ. Neonatal herpes simplex virus infection: follow-up evaluation of vidarabine therapy. Pediatrics. 1983;72:778-85.

Yeager AS, Arvin AM. Reasons for the absence of a history of recurrent genital infections in mothers of neonates infected with herpes simplex virus. Pediatrics. 1984;73:188-93.